Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 3.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 82,399 shares of the company’s stock after acquiring an additional 2,788 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Moderna were worth $3,426,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. State Street Corp increased its position in Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after buying an additional 178,115 shares during the period. Wellington Management Group LLP increased its holdings in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after buying an additional 906,114 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Moderna by 0.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after buying an additional 19,819 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in Moderna by 6.2% in the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after acquiring an additional 178,939 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Stock Down 3.9 %

Shares of MRNA stock opened at $39.42 on Friday. The firm has a fifty day moving average of $40.89 and a two-hundred day moving average of $61.32. Moderna, Inc. has a 1-year low of $31.94 and a 1-year high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period last year, the firm earned ($1.39) earnings per share. On average, sell-side analysts anticipate that Moderna, Inc. will post -9.26 EPS for the current fiscal year.

Insider Transactions at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Argus downgraded Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Jefferies Financial Group dropped their target price on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research report on Tuesday, October 15th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Evercore ISI dropped their price objective on shares of Moderna from $60.00 to $50.00 and set an “in-line” rating for the company in a research report on Monday, January 27th. Finally, Bank of America restated an “underperform” rating and set a $41.00 target price on shares of Moderna in a report on Tuesday, December 10th. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $67.26.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.